Q2 FY2026 EarningsQ2 FY2026 results significantly beat consensus on the top line, with revenue of $496.0M vs. $457.4M expected, driven by the strong performance of LUMRYZ ($96.6M). GAAP EPS of $0.00 exceeded the anticipated loss of -$0.03. While the company maintained its FY2026 revenue guidance, it lowered GAAP Net Income expectations due to a non-cash $26.4M charge related to contingent consideration for the Avadel acquisition, following positive clinical results.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Alkermes(ALKS) the Revenue is 496.01 M (+26.97%), Beat estimate;the EBIT is 18.35 M (-80.26%), Beat estimate;the EPS is 0 (-100%), Beat estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
0.50B26.97%
0.46B17.07%
+0.04B9.90%
EBITExceed expectations
0.02B80.26%
0.02B82.24%
+0.00B1.98%
EPSExceed expectations
0100.00%
-0.0286105.50%
+0.02865.50%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf